Abstracts Archive - Page 480 of 2425 - ACR Meeting Abstracts

Abstract Number: 2174 • ACR Convergence 2022
Influence of Immunosuppressive Therapy on Gastrointestinal Symptoms in Patients with Systemic Sclerosis
Lea Stamm¹, Alexandru Garaiman¹, Norina Zampatti¹, Mike Becker¹, Cosimo Bruni¹, Rucsandra Dobrota¹, Muriel Elhai¹, Sherif Ismail², Suzana Jordan¹, Aurora Tatu³, Oliver Distler¹ and Carina Mihai¹, ¹Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, ²Department of Internal Medicine, National Research Center, Cairo, Egypt, ³Department of Gastroenterology, University Hospital Zurich, University of Zurich, Zürich, Switzerland
Background/Purpose: The gastrointestinal (GI) tract is frequently affected in systemic sclerosis (SSc), leading to considerable morbidity and even mortality. While important progress has been made…
Abstract Number: 2141 • ACR Convergence 2022
How Well Does Ultrasound-assessed Synovitis in Reduced Joint Sets Predict the Response to Secukinumab in Patients with Active Psoriatic Arthritis and Inadequate Response to Conventional DMARDs? – Exploratory Results from a Phase 3b Study
Maria-Antonietta D'Agostino¹, Philip G Conaghan², Corine Gaillez³, Esperanza Naredo⁴, Peter mandl⁵, Philippe Carron⁶, Ladislav Šenolt⁷, Javier Eduardo Rosa⁸, Alejandra Lopez Rdz⁹, Punit Goyanka¹⁰, Braja Gopal Sahoo¹⁰, Weibin Bao¹¹, Georg Schett¹² and Maarten Boers¹³, ¹Catholic University of Sacred Heart, Roma, Italy, ²University of Leeds, Leeds, United Kingdom, ³Novartis Pharma AG, Basel, Switzerland, ⁴Hospital General Universitario Gregorio Marañón and Complutense University, Madrid, Spain, ⁵Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Wien, Austria, ⁶Ghent University Hospital, Ghent, Belgium, ⁷Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ⁸Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁹Dermatológico Country, PSOAPS Psoriasis Clinical and Research Centre, Guadalajara, Mexico, ¹⁰Novartis Healthcare Pvt Ltd, Hyderabad, India, ¹¹Novartis Pharmaceuticals Corporation, East Hanover, NJ, ¹²Universitätsklinikum Erlangen, Erlangen, Germany, ¹³Amsterdam UMC, Vrije Universiteit, Amsterdam, Netherlands
Background/Purpose: Power Doppler ultrasound (PDUS) allows the visualization of morphological and inflammatory changes of the synovium. The ULTIMATE study (NCT02662985) was the first large, randomized,…
Abstract Number: 2193 • ACR Convergence 2022
Invasive Fungal Diseases in Patients with Autoimmune Diseases: Prospective Data from a Nationwide French Registry
Simon Galmiche¹, Benjamin Thoreau², Stéphane Bretagne³, Alexandre Alanio³, André Paugam⁴, Valérie Bru⁵, Sophie Cassaing⁶, Jean-Pierre Gangneux⁷, Hélène Guégan⁷, Loïc Favennec⁸, Alida Minoza⁹, Florent Morio¹⁰, Julie Bonhomme¹¹, Guillaume Desoubeaux¹², Odile Eloy¹³, Lilia Hasseine¹⁴, Milène Sasso¹⁵, Laurence Millon¹⁶, Anne-Pauline Bellanger¹⁶, Philippe Poirier¹⁷, Maxime Moniot¹⁷, Taieb Chouaki¹⁸, Antoine Huguenin¹⁹, Frédéric Dalle²⁰, Bernard Bouteille²¹, Muriel Nicolas²², Nicole Desbois-Nogard²³, Marie-Elisabeth Bougnoux²⁴, François Danion²⁵, Vincent Poindron²⁶, Antoine Néel²⁷, Karine Boukris-Sitbon²⁸, Fanny Lanternier²⁹ and Benjamin Terrier³⁰, ¹Institut Pasteur, Paris, France, ²AP-HP, Université Paris Cité, INSERM U1016, CNR UMR 8104, Paris, France, ³Institut Pasteur, Université Paris Cité, Centre National de Référence Mycoses Invasives et Antifongiques, UMR 2000, AP-HP, Paris, France, ⁴Parasitologie – Mycologie, Université Paris Cité, Cochin Hospital, AP-HP, Paris, France, ⁵Institut de parasitologie et de pathologie tropicale, Hôpitaux universitaires de Strasbourg, Université de Strasbourg, Strasbourg, France, ⁶Parasitologie - Mycologie, Université de Toulouse, CHU de Toulouse, Toulouse, France, ⁷Université de Rennes, CHU, INSERM, Irset: Institut de Recherche en Santé, Environnement et Travail, UMR_S 1085, Rennes, France, ⁸French National Cryptosporidiosis Reference Center, Rouen University Hospital, Rouen, France, ⁹Département des agents infectieux, Service de Mycologie-Parasitologie, CHU de Poitiers, Poitiers, France, ¹⁰Parasitologe – Mycologie, CHU de Nantes, Nantes, France, ¹¹Microbiologie, CHU de Caen, Caen, France, ¹²Parasitologie - Mycologie - Médecine tropicale, CHU de Tours, Tours, France, ¹³Microbiologie, Hôpital de Versailles, Le Chesnay, France, ¹⁴Parasitologie – Mycologie, hôpital de l'Archet, CHU Nice, Nice, France, ¹⁵Laboratoire de Parasitologie-Mycologie, CHU Nîmes, Université de Montpellier, CNRS, IRD, MiVEGEC, Nîmes, France, ¹⁶Laboratoire de Parasitologie – Mycologie, CHU Besançon, Besançon, France, ¹⁷Parasitologie – Mycologie, CHU de Clermont-Ferrand, Clermont-Ferrand, France, ¹⁸Mycologie – parasitologie, CHU d’Amiens, Amiens, France, ¹⁹Parasitologie – Mycologie, hôpital Maison-Blanche, CHU de Reims, Reims, France, ²⁰Parasitologie – Mycologie, Plateforme de Biologie Hospitalo-Universitaire Gérard Mack, Dijon, France, ²¹Parasitologie – Mycologie, Centre de Biologie et de Recherche en Santé, CHU Dupuytren, Limoges, France, ²²Mycologie – Parasitologie, CHU de Pointe-à-pitre/Abymes, Pointe-à-Pitre, France, ²³Parasitologie – Mycologie, CHU de la Martinique, Fort-de-France, France, ²⁴Institut Pasteur, Unité Biologie et Pathogénicité Fongiques, Département Mycologie, Laboratoire de Parasitologie – Mycologie, Service de Microbiologie, Necker-Enfants Malades University Hospital, AP-HP, Paris, France, ²⁵Maladies infectieuses et tropicales, Hôpitaux universitaires de Strasbourg, Strasbourg, France, ²⁶Immunologie clinique et médecine interne, Hôpitaux universitaires de Strasbourg, Strasbourg, France, ²⁷CHU de Nantes, Nantes, France, ²⁸Institut Pasteur, Université Paris Cité, CNRS, Mycologie Moléculaire, Centre National de Référence Mycoses Invasives et Antifongiques, UMR 2000, Paris, France, ²⁹Infectious Diseases Unit, Necker-Enfants Malades University Hospital, AP-HP, Institut Pasteur, Université Paris Cité, Centre National de Référence Mycoses Invasives et Antifongiques, CNRS UMR 2000, Paris, France, ³⁰National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris, France
Background/Purpose: Patients with autoimmune diseases (AIDs) display a risk of invasive fungal diseases (IFDs), because of the underlying disease or treatments used. Our objective was…
Abstract Number: 2195 • ACR Convergence 2022
Pre-exposure Prophylaxis for SARS-CoV-2 with Subcutaneous Casirivimab/Imdevimab in Vaccine-refractory Patients with Immune-mediated Inflammatory Diseases
Filippo Fagni¹, Katja Schmidt², Daniela Bohr³, Larissa Valor Mendez⁴, Ioanna Minopoulou², Melek Yalcin Mutlu², Fabian Hartmann², Koray Tascilar⁴, Karin Manger⁵, Bernhard Manger², Arnd Kleyer⁴, David Simon⁴, Georg Schett⁶ and Thomas Harrer², ¹University Hospital Erlangen; Department of Internal Medicine 3 - Rheumatology and Immunology, Erlangen, Germany, ²University Hospital Erlangen, Department of Internal Medicine 3 - Rheumatology and Immunology, Erlangen, Germany, ³Department of Internal Medicine 3, Rheumatology & Immunology, Friedrich-Alexander-University (FAU) Erlangen-Nurnberg and University Hospital Erlangen, Erlangen, Germany, ⁴Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054 Erlangen, Germany; Deutsches Zentrum Immuntherapie, Friedrich-Alexander-UniversityErlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, ⁵Rheumatology Practice Bamberg, Bamberg, Germany, ⁶Universitätsklinikum Erlangen, Erlangen, Germany
Background/Purpose: Humoral responses to SARS-CoV-2 vaccination are reduced in patients with immune-mediated inflammatory diseases (IMID), especially when treated with B-cell depletion therapies, leading to increased…
Abstract Number: 2178 • ACR Convergence 2022
BNT162b2 mRNA Vaccine Against Covid 19, Humoral Response, Safety and Efficacy in Scleroderma Patients
Yolanda Braun-Moscovici¹, Marielle Kaplan¹, Maya Braun², Doron Markovits³, Sami Giryes³, Kohava Toledano³, Yonit Tavor³, Katya Dolnikov³, Rula Daood³ and Alexandra Balbir-Gurman⁴, ¹Rambam Health Care Campus and Rappaport Faculty of Medicine, Haifa, Israel, ²Hebrew University of Jerusalem, Bioinformatics, Jerusalem, Israel, ³Rambam Health Care Campus, Haifa, Israel, ⁴Rheumatology Institute, Rambam Health Care Campus, Haifa, Israel
Background/Purpose: In the begining of pandemic and till spring 2021 there were no clinical and laboratory data regarding sefety and efficacy of mRNA vaccines against…
Abstract Number: 2186 • ACR Convergence 2022
Cellular and Humoral Responses Following SARS-CoV-2 mRNA Vaccination in Patients on PD-1 Immunotherapy with irAEs
Sokratis Apostolidis¹, Paulina Coutifaris², Mark Painter³, Ajinkya Pattekar², Rishi Goel¹, divij mathew², Wenzhao Meng², Kevin Wang², Bria Fulmer², Angela Corrigan², Kendall Lundgreen², Elizabeth Drapeau², Derek Oldridge², Josephine Giles², Amy Baxter², Sasikanth Manne², Michelle Mckeague², Ahron Flowers², Oliva Kuthuru², Sherea Long², Jeanette Dougherty², Sigrid Gouma², Justine Williams², Maura McLaughlin², Sharon Adamski², Alba Grifoni⁴, Daniela Weiskopf⁴, Alessandro Sette⁴, Scott Hensley², Paul Bates², Eline Luning Prak¹, Laura Vella², Giorgos Karakousis², Ravi Amaravadi², Suzanne McGettigan², Kristin Kreider², Tara Mitchell², Allison Greenplate², Lynn Schuchter², Alexander Huang² and E. John Wherry¹, ¹University of Pennsylvania, Philadelphia, PA, ²UPenn, Philadelphia, ³UPenn, Philadelphia, PA, ⁴LJI, La Jolla
Background/Purpose: Patients with cancer exhibit increased mortality from SARS-CoV-2 infection compared to the general population. SARS-CoV-2 mRNA vaccination in healthy individuals generates effective and long-lasting…
Abstract Number: 2192 • ACR Convergence 2022
Serious Infections in Offspring Exposed During Late Pregnancy to Tumour Necrosis Factor Inhibitors with High versus Low Placental Transfer Ability
Leah K. Flatman¹, Yvan St. Pierre², Isabelle Malhamé³, Olga Basso¹, Anick Berard⁴, Sasha Bernatsky² and Evelyne Vinet³, ¹McGill University, Montréal, QC, Canada, ²Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ³McGill University Health Centre, Montréal, QC, Canada, ⁴University of Montreal, Montréal, QC, Canada
Background/Purpose: During pregnancy, best practice guidelines suggest discontinuing tumour necrosis factor inhibitors (TNFi) with high placental transfer before or during the third trimester if the…
Abstract Number: 2188 • ACR Convergence 2022
The Effect of Group-based Cognitive Behavioral Therapy for Insomnia in People with Rheumatoid Arthritis: A Randomized Controlled Trial
Kristine Latocha¹, Katrine Loeppenthin², Mikkel Østergaard³, poul jennum⁴, Merete L Hetland⁵, Henrik Rogind⁶, Tine Lundbak⁶, Julie Midtgaard⁷, Robin Christensen⁸ and Bente Esbensen⁵, ¹Copenhagen University Hospital - Rigshospitalet, Glostrup, Denmark, ²Department of Oncology, Copenhagen University Hospital - Rigshospitalet, Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark, ³Rigshospitalet, University of Copenhagen, Glostrup, Denmark, ⁴Danish Center for Sleep Medicine, Department of Clinical Neurophysiology, Copenhagen University Hospital - Rigshospitalet, Glostrup,Department of Clinical Medicine, University of Copenhagen, Copenhagen, ⁵Rigshospitalet, Glostrup, Denmark, ⁶Center for Rheumatology and Spine Diseases, Copenhagen University Hospital -Rigshospitalet, Glostrup, Denmark, ⁷Mental Health Centre Glostrup, University of Copenhagen, Glostrup,Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark, ⁸Musculoskeletal Statistics Unit, The Parker Institute, Copenhagen, Denmark
Background/Purpose: Insomnia is highly prevalent in people with rheumatoid arthritis (RA) and may exacerbate symptoms and burdens, such as fatigue, depressive symptoms, and pain (1).…
Abstract Number: 2137 • ACR Convergence 2022
Impact of Patient Characteristics, Including Sex, on the Efficacy of Upadacitinib Compared with Adalimumab in Patients with Psoriatic Arthritis
Lihi Eder¹, Laura Coates², Peter Nash³, Uta Kiltz⁴, Ennio Lubrano⁵, Erin McDearmon-Blondell⁶, Tianming Gao⁷ and Alexis Ogdie⁸, ¹Women’s College Research Institute, Department of Medicine, University of Toronto, Toronto, ON, Canada, ²Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK, Oxford, England, United Kingdom, ³School of Medicine, Griffith University, Brisbane, Australia, ⁴Rheumazentrum Ruhrgebiet, Herne, Germany, ⁵Academic Rheumatology Unit, Dipartimento di Medicina e Scienze della Salute ‘‘Vincenzo Tiberio’’, Università degli Studi del Molise, Campobasso, Italy, ⁶AbbVie, Inc., Mettawa, IL, ⁷AbbVie, Inc., North Chicago, IL, ⁸Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
Background/Purpose: Evidence suggests that response to treatment in PsA may vary with patient (pt) characteristics, such as sex.1 This post hoc analysis of the Phase…
Abstract Number: 2140 • ACR Convergence 2022
Exposure-Adjusted Incidence Rate for Adverse Events of Special Interest in Patients with Psoriatic Arthritis Treated with Apremilast
Philip J Mease¹, Dafna Gladman², Georg Schett³, Maria Paris⁴, Sue Cheng⁵, Sven Richter⁵, Lichen Teng⁵ and Arthur Kavanaugh⁶, ¹Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, ²Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, ON, Canada, ³Universitätsklinikum Erlangen, Erlangen, Germany, ⁴Amgen Inc., Westfield, NJ, ⁵Amgen, Inc., Thousand Oaks, CA, ⁶University of California San Diego, La Jolla, CA
Background/Purpose: Psoriatic arthritis (PsA) is a chronic systemic inflammatory musculoskeletal disease. The potential relationship between PsA therapies and specific safety events such as major adverse…
Abstract Number: 2175 • ACR Convergence 2022
Evaluation of the Distribution of Haemodynamic Parameters and Prognostic Impact in a Cohort of Patients with Systemic Sclerosis
Zoe Brown¹, Dylan Hansen², Wendy Stevens², Laura Ross¹, Nava Ferdowsi², Susanna Proudman³, Jenny Walker⁴, Jo Sahhar⁵, Gene-Siew Ngian⁶, Lauren Host⁷, Gabor Major⁸, Mandana Nikpour⁹ and Kathleen Morrisroe², ¹St Vincent's Hospital, Melbourne, Australia, ²St Vincent's Hospital Melbourne, Melbourne, Australia, ³University of Adelaide, Medindie, Australia, ⁴Flinders Medical Centre, Flinders University, Daw Park, Australia, ⁵Monash Health, Melbourne, Australia, ⁶Melbourne Health, Northcote, Australia, ⁷Fiona Stanley Hospital, London, United Kingdom, ⁸Hunter New England Health Service, Rankin Park - Newcastle, New South Wales, Australia, ⁹The University of Melbourne at St. Vincent's Hospital Melbourne, Melbourne, Australia
Background/Purpose: Scleroderma (SSc) is a complex multisystem autoimmune disease, characterised by vasculopathy and fibrosis of skin and organs. Involvement of the cardiovascular system occurs frequently…
Abstract Number: 2131 • ACR Convergence 2022
Minimal Disease Activity Response Patterns in Bio-Naïve Patients Treated with Guselkumab: A Machine Learning Analysis
Alen Zabotti¹, Sarah Ohrndorf², William Tillett³, Marlies Neuhold⁴, Michel van Speybroeck⁵, Elke Theander⁶, Christine Contré⁷, Mohamed Sharaf⁸, May Shawi⁹, Michelle Perate¹⁰, Alexa Kollmeier¹¹ and Pascal Richette¹², ¹Department of Medical and Biological Sciences, Rheumatology Unit, University of Udine, Udine, Italy, ²Charité Universitätsmedizin Berlin, Berlin, Germany, ³Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ⁴Takeda Europe & Canada Business Unit (EUCAN) Medical Affairs, Zurich, Switzerland; formerly at Janssen Scientific Affairs, LLC, Zug, Switzerland, ⁵Janssen Pharmaceutica, Beerse, Belgium, ⁶Janssen Cilag, Lund, Sweden, ⁷Formerly at Janssen Scientific Affairs, LLC, Issy-les-Moulineaux, France, Issy-les-Moulineaux, France, ⁸Johnson & Johnson, Middle East FZ LLC, Dubai, United Arab Emirates, ⁹Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, ¹⁰Janssen Scientific Affairs, LLC, Horsham, PA, ¹¹Janssen-Cilag, Research & Development, LLC, San Diego, CA, ¹²Department of Rheumatology, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Paris, France
Background/Purpose: Guselkumab (GUS), a human monoclonal antibody targeting the interleukin-23p19 subunit, demonstrated joint and skin efficacy in patients with active psoriatic arthritis (PsA) in the…
Abstract Number: 1782 • ACR Convergence 2022
Sociocultural and Moral Factors Influencing the Decision to Vaccinate Among Rheumatic Patients: A Qualitative Study
Tirsa Colmenares-Roa¹, Amaranta ManriquedeLara², Virginia Pascual Ramos³, JOSE FRANCISCO MOCTEZUMA RIOS⁴, Irazu Contreras-Ibañez⁵, Everardo Alvarez-Hernandez⁶, Guillermo Guaracha Basañez⁷, Graciela Meza-LópezyOlguin⁴ and Ingris Pelaez-Ballestas¹, ¹Hospital General de México "Dr. Eduardo Liceaga", Ciudad de México, Mexico, ²Hospital General de México "Dr. Eduardo Liceaga,", Ciudad de México, Mexico, ³Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Ciudad de México, Mexico, ⁴HOSPITAL GENERAL DE MEXICO "Dr. Eduardo Liceaga", Ciudad de México, Mexico, ⁵Instituto Nacional de Nutricion Salvador Zubirán, Ciudad de México, Mexico, ⁶Hospital General de Mexico "Dr.Eduardo Liceaga", Ciudad de México, Mexico, ⁷Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirn", Ciudad de México, Mexico
Background/Purpose: Vaccination is a process that involves individual, social and moral aspects, beyond public governance of vaccines or vaccination as a public health concern. The…
Abstract Number: 1785 • ACR Convergence 2022
PROs and Sociodemographic Factors in Year Prior to COVID Predict Trajectories of Depressive Symptoms in Adults with RA in First 2 Years of Pandemic: Data from the Canadian Early Arthritis Cohort
Susan Bartlett¹, orit schieir², Marie-France Valois², Janet Pope³, Louis Bessette⁴, Gilles Boire⁵, Carol Hitchon⁶, Edward Keystone⁷, Carter Thorne⁸, Diane Tin⁹, Glen Hazlewood¹⁰ and Vivian Bykerk¹¹, ¹McGill University, Montreal, QC, Canada, ²McGill University, Montréal, QC, Canada, ³University of Western Ontario, London, ON, Canada, ⁴Centre de l'Ostoporose et de Rhumatologie de Québec, Québec, QC, Canada, ⁵Universite de Sherbrooke, Sherbrooke, QC, Canada, ⁶University of Manitoba, Winnipeg, MB, Canada, ⁷Keystone Consulting Enterprises Inc., Toronto, ON, Canada, ⁸Southlake Regional Health Centre, Newmarket, ON, Canada, ⁹The Arthritis Program Research Group, Newmarket, ON, Canada, ¹⁰University of Calgary, Calgary, AB, Canada, ¹¹Hospital for Special Surgery, New York, NY
Background/Purpose: Growing evidence points to considerable mental health impacts of the prolonged COVID-19 pandemic, though data from longitudinal studies in rheumatic diseases are sparse. We…
Abstract Number: 2138 • ACR Convergence 2022
Real-world Persistence and Treatment Patterns in Psoriatic Arthritis Patients Treated with Anti-IL17 Therapy
BEATRIZ E. JOVEN¹, Concepción Fito Manteca², Enrique Rubio³, Enrique Raya Álvarez⁴, Alba Pérez⁵, Raquel Hernández⁶, Sara Manrique Arija⁷, Mercedes Núñez⁸, Silvia Díaz⁸, Luis Trancho⁸, Sebastian Moyano⁸, Alessandra Lacetera⁹, Noelia Alfaro-Oliver⁹ and Rosario Garcia-Vicuña¹⁰, ¹Hospital Universitario 12 de Octubre, Madrid, Spain, ²Hospitalario de Navarra, Pamplona, Spain, ³Division of Rheumatology, Hospital Universitario Virgen del Rocío, Sevilla, Spain, ⁴Hospital Universitario San Cecilio, Granada, Spain, ⁵Hospital Puerta del Mar, Cádiz, Spain, ⁶Virgen de Valme University Hospital, Sevilla, Spain, ⁷Hospital Regional Universitario Málaga, Málaga, Spain, ⁸Lilly, Alcobendas, Spain, ⁹OXON Epidemiology, Madrid, Spain, ¹⁰Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Spain
Background/Purpose: Interleukin-17A inhibitors (anti-IL17) have provided an additional treatment option in the management of the psoriatic arthritis (PsA). This study aims to describe the patient…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].